---
category: news
title: "Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018"
excerpt: "Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small molecule ATR inhibitor that targets DNA Damage Response (DDR) pathways. The Phase I study will evaluate the safety,"
publishedDateTime: 2022-04-26T23:30:00Z
originalUrl: "https://us.acrofan.com/detail.php?number=653478"
webUrl: "https://us.acrofan.com/detail.php?number=653478"
type: article
quality: 18
heat: 18
published: false

provider:
  name: 아크로팬
  domain: acrofan.com

topics:
  - AI Ethics
  - AI

images:
  - url: "http://us.acrofan.com/img/noImg.jpg"
    width: 500
    height: 324
    isCached: true

secured: "14oBx2AvT4ghbBmlw46VgjFTLoA6zaxsfY2PEq0s3P7gdPxJLErMKCuxhD2P8lT5ZkVVVCkywSgJmw2gPObQ0Uw+trggJgtJxjsgzEaZ5FVWNAxSRmVRbeUixjH2L5ZaxshH7eUSc5pAf89FL/8QEqkVZ8K+SSYva/VgOG6BSAo2umKB6sv7QDjeXsXd1lW6Kvc1RYSK4DY93yzYZlt8fGKQ6BECwoD8zfO2sgg/cBUKA/NYhLGPsdEXviFs3rw/ByClaEqCmPtmA1rPsBqNqKQnOMZvWOuPToxFg4yHIOAj6zs5vws4xhtYOOOiCjPSmlNxR8I4ObtO1Ubwc+ohtt5URWiqpBcpBGCREIAUDHA=;wwborTeFUWMalZFsZaFRXg=="
---

